Significados de pegylate interferon en inglés

Recommendations from HCV-HIV International Panel advise current treatment with pegylated interferon plus ribavirin.

Up to now, experience with pegylated interferon and ribavirin is scarce in this population.

Use of pegylated interferon was more frequent in Poland and Romania than in other countries.

The current standard in hepatitis C treatment consists of combination regimens of pegylated interferon-alpha plus ribavirin.

Background: Many patients with chronic hepatitis C have not responded to therapy with pegylated interferon plus ribavirin.

Biologic therapy was continued and the infection was successfully treated with pegylated interferon, which achieved a sustained virologic response.

Conclusions: Transaminase elevations during treatment of chronic Hepatitis C virus with pegylated interferon and ribavirin are common but rarely severe.

Hence pegylated interferon plus ribavirin in full doses is effective pre and post transplant but has a low SVR rate.

Hepatic steatosis is associated with increased hepatic fibrosis and a reduced level of sustained virological response to pegylated interferon and ribavirin.

Treatment of chronic hepatitis C with pegylated interferon-a and ribavirin is now adapted individually based on the virological response on treatment.

Interferon alfa, pegylated interferon alfa and five direct antiviral nucleoside and nucleotide analogues are approved for the treatment of chronic hepatitis B.

Four patients are still receiving pegylated interferon at a mean duration of 20 months (range, 15-32 months).

Serum samples from HDV-positive patients taken before treatment with pegylated interferon-a2a and at treatment weeks 12 and 48 were studied.

Methods: All HIV-HCV-coinfected patients who underwent hepatic elastography before initiating a course of pegylated interferon plus ribavirin therapy at 2 Spanish clinics were retrospectively identified.

Placebo and nitazoxanide were administered as an add-on therapy to pegylated interferon a-2a plus ribavirin following a 12-week lead-in phase.

Five patients experienced virologic clearance, 2 in whom virus cleared spontaneously and 3 who were treated with pegylated interferon and ribavirin.